All posts by: Michael Zand

About Michael Zand

3 Questions: Angela Belcher and Kristala Prather on the promise of energy bioscience – MIT News

Continue reading

2017-07-10 NEWS

MIT News

3 Questions: Angela Belcher and Kristala Prather on the promise of energy bioscience
MIT News
Drawing upon MIT’s extensive existing research capability in synthetic biology, microbial metabolic engineering, new DNA technologies, and directed evolution, the center plans to rapidly screen, model, design, and synthesize new materials with

Continue reading

2017-07-10 NEWS

Multiple Sclerosis News Today

Experts Call for Tighter Regulation of Stem Cell Therapies in Use at Clinics Worldwide
Multiple Sclerosis News Today
Advertising for stem cell therapies not supported by clinical research — often made directly to patients and sometimes promoted as a “cure” for diseases like multiple sclerosis or Parkinson’s — is a growing problem that needs to be addressed and

Continue reading

2017-07-10 NEWS

Broad Institute Joins CRISPR Patent Pool Talks
Genetic Engineering & Biotechnology News (blog)
The Broad Institute of MIT and Harvard said today it has joined discussions to create a non-exclusive CRISPR-Cas9 joint licensing pool being coordinated by MPEG LA, which operates patent pool licensing programs across institutions and countries.

Continue reading

2017-07-10 NEWS

Reuters

FDA panel to focus on safety of Novartis gene therapy drug
Reuters
(Reuters) – The U.S. Food and Drug Administration will ask a panel of advisors to focus on the safety of Novartis AG’s experimental gene therapy drug when it meets to review the product on Wednesday. The keenly anticipated preliminary review of the …
FDA Advisory Board and Novartis to Discuss Leukemia Gene Therapy WednesdayRare Disease Report
What to watch for as Novartis heads to the FDA with a novel cancer therapySTAT

all 10 news articles »